One of the most commonly used classes of drugs to treat depression is selective serotonin reuptake inhibitors (SSRIs), and another class of antidepressants is serotonin and norepinephrine reuptake inhibitors (SNRIs). SNRIs play an important role in regulating emotion and sensitivity to pain. The biggest feature is that it can improve the physical pain symptoms associated with depression, and its side effects on sexual function are far less than other first-line drugs. They mainly include Venlafaxine and Duloxetine.
The global SNRIs Antidepressants market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The “SNRIs Antidepressants Industry Forecast” looks at past sales and reviews total world SNRIs Antidepressants sales in 2023, providing a comprehensive analysis by region and market sector of projected SNRIs Antidepressants sales for 2024 through 2030. With SNRIs Antidepressants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world SNRIs Antidepressants industry.
This Insight Report provides a comprehensive analysis of the global SNRIs Antidepressants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on SNRIs Antidepressants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global SNRIs Antidepressants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for SNRIs Antidepressants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global SNRIs Antidepressants.
United States market for SNRIs Antidepressants is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for SNRIs Antidepressants is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for SNRIs Antidepressants is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key SNRIs Antidepressants players cover Eli Lilly, Shanghai Zhongxi, Jiangsu Enhua Pharmaceutical, Pfizer and Kanghong Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of SNRIs Antidepressants market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Venlafaxine
Duloxetine
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Shanghai Zhongxi
Jiangsu Enhua Pharmaceutical
Pfizer
Kanghong Pharmaceutical
Aurobindo
Zydus
Teva
Renfu Pharmaceutical
Suzhou Fourth Pharmaceutical Factory
Sandoz
Shandong Xinqi Pharmaceutical
Chongqing Yaoyou Pharmaceutical
Lupin
Sun Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global SNRIs Antidepressants market?
What factors are driving SNRIs Antidepressants market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do SNRIs Antidepressants market opportunities vary by end market size?
How does SNRIs Antidepressants break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global SNRIs Antidepressants Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for SNRIs Antidepressants by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for SNRIs Antidepressants by Country/Region, 2019, 2023 & 2030
2.2 SNRIs Antidepressants Segment by Type
2.2.1 Venlafaxine
2.2.2 Duloxetine
2.3 SNRIs Antidepressants Sales by Type
2.3.1 Global SNRIs Antidepressants Sales Market Share by Type (2019-2024)
2.3.2 Global SNRIs Antidepressants Revenue and Market Share by Type (2019-2024)
2.3.3 Global SNRIs Antidepressants Sale Price by Type (2019-2024)
2.4 SNRIs Antidepressants Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 SNRIs Antidepressants Sales by Application
2.5.1 Global SNRIs Antidepressants Sale Market Share by Application (2019-2024)
2.5.2 Global SNRIs Antidepressants Revenue and Market Share by Application (2019-2024)
2.5.3 Global SNRIs Antidepressants Sale Price by Application (2019-2024)
3 Global SNRIs Antidepressants by Company
3.1 Global SNRIs Antidepressants Breakdown Data by Company
3.1.1 Global SNRIs Antidepressants Annual Sales by Company (2019-2024)
3.1.2 Global SNRIs Antidepressants Sales Market Share by Company (2019-2024)
3.2 Global SNRIs Antidepressants Annual Revenue by Company (2019-2024)
3.2.1 Global SNRIs Antidepressants Revenue by Company (2019-2024)
3.2.2 Global SNRIs Antidepressants Revenue Market Share by Company (2019-2024)
3.3 Global SNRIs Antidepressants Sale Price by Company
3.4 Key Manufacturers SNRIs Antidepressants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers SNRIs Antidepressants Product Location Distribution
3.4.2 Players SNRIs Antidepressants Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for SNRIs Antidepressants by Geographic Region
4.1 World Historic SNRIs Antidepressants Market Size by Geographic Region (2019-2024)
4.1.1 Global SNRIs Antidepressants Annual Sales by Geographic Region (2019-2024)
4.1.2 Global SNRIs Antidepressants Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic SNRIs Antidepressants Market Size by Country/Region (2019-2024)
4.2.1 Global SNRIs Antidepressants Annual Sales by Country/Region (2019-2024)
4.2.2 Global SNRIs Antidepressants Annual Revenue by Country/Region (2019-2024)
4.3 Americas SNRIs Antidepressants Sales Growth
4.4 APAC SNRIs Antidepressants Sales Growth
4.5 Europe SNRIs Antidepressants Sales Growth
4.6 Middle East & Africa SNRIs Antidepressants Sales Growth
5 Americas
5.1 Americas SNRIs Antidepressants Sales by Country
5.1.1 Americas SNRIs Antidepressants Sales by Country (2019-2024)
5.1.2 Americas SNRIs Antidepressants Revenue by Country (2019-2024)
5.2 Americas SNRIs Antidepressants Sales by Type
5.3 Americas SNRIs Antidepressants Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC SNRIs Antidepressants Sales by Region
6.1.1 APAC SNRIs Antidepressants Sales by Region (2019-2024)
6.1.2 APAC SNRIs Antidepressants Revenue by Region (2019-2024)
6.2 APAC SNRIs Antidepressants Sales by Type
6.3 APAC SNRIs Antidepressants Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe SNRIs Antidepressants by Country
7.1.1 Europe SNRIs Antidepressants Sales by Country (2019-2024)
7.1.2 Europe SNRIs Antidepressants Revenue by Country (2019-2024)
7.2 Europe SNRIs Antidepressants Sales by Type
7.3 Europe SNRIs Antidepressants Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa SNRIs Antidepressants by Country
8.1.1 Middle East & Africa SNRIs Antidepressants Sales by Country (2019-2024)
8.1.2 Middle East & Africa SNRIs Antidepressants Revenue by Country (2019-2024)
8.2 Middle East & Africa SNRIs Antidepressants Sales by Type
8.3 Middle East & Africa SNRIs Antidepressants Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of SNRIs Antidepressants
10.3 Manufacturing Process Analysis of SNRIs Antidepressants
10.4 Industry Chain Structure of SNRIs Antidepressants
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 SNRIs Antidepressants Distributors
11.3 SNRIs Antidepressants Customer
12 World Forecast Review for SNRIs Antidepressants by Geographic Region
12.1 Global SNRIs Antidepressants Market Size Forecast by Region
12.1.1 Global SNRIs Antidepressants Forecast by Region (2025-2030)
12.1.2 Global SNRIs Antidepressants Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global SNRIs Antidepressants Forecast by Type
12.7 Global SNRIs Antidepressants Forecast by Application
13 Key Players Analysis
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly SNRIs Antidepressants Product Portfolios and Specifications
13.1.3 Eli Lilly SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Shanghai Zhongxi
13.2.1 Shanghai Zhongxi Company Information
13.2.2 Shanghai Zhongxi SNRIs Antidepressants Product Portfolios and Specifications
13.2.3 Shanghai Zhongxi SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Shanghai Zhongxi Main Business Overview
13.2.5 Shanghai Zhongxi Latest Developments
13.3 Jiangsu Enhua Pharmaceutical
13.3.1 Jiangsu Enhua Pharmaceutical Company Information
13.3.2 Jiangsu Enhua Pharmaceutical SNRIs Antidepressants Product Portfolios and Specifications
13.3.3 Jiangsu Enhua Pharmaceutical SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Jiangsu Enhua Pharmaceutical Main Business Overview
13.3.5 Jiangsu Enhua Pharmaceutical Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer SNRIs Antidepressants Product Portfolios and Specifications
13.4.3 Pfizer SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Kanghong Pharmaceutical
13.5.1 Kanghong Pharmaceutical Company Information
13.5.2 Kanghong Pharmaceutical SNRIs Antidepressants Product Portfolios and Specifications
13.5.3 Kanghong Pharmaceutical SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Kanghong Pharmaceutical Main Business Overview
13.5.5 Kanghong Pharmaceutical Latest Developments
13.6 Aurobindo
13.6.1 Aurobindo Company Information
13.6.2 Aurobindo SNRIs Antidepressants Product Portfolios and Specifications
13.6.3 Aurobindo SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Aurobindo Main Business Overview
13.6.5 Aurobindo Latest Developments
13.7 Zydus
13.7.1 Zydus Company Information
13.7.2 Zydus SNRIs Antidepressants Product Portfolios and Specifications
13.7.3 Zydus SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Zydus Main Business Overview
13.7.5 Zydus Latest Developments
13.8 Teva
13.8.1 Teva Company Information
13.8.2 Teva SNRIs Antidepressants Product Portfolios and Specifications
13.8.3 Teva SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Teva Main Business Overview
13.8.5 Teva Latest Developments
13.9 Renfu Pharmaceutical
13.9.1 Renfu Pharmaceutical Company Information
13.9.2 Renfu Pharmaceutical SNRIs Antidepressants Product Portfolios and Specifications
13.9.3 Renfu Pharmaceutical SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Renfu Pharmaceutical Main Business Overview
13.9.5 Renfu Pharmaceutical Latest Developments
13.10 Suzhou Fourth Pharmaceutical Factory
13.10.1 Suzhou Fourth Pharmaceutical Factory Company Information
13.10.2 Suzhou Fourth Pharmaceutical Factory SNRIs Antidepressants Product Portfolios and Specifications
13.10.3 Suzhou Fourth Pharmaceutical Factory SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Suzhou Fourth Pharmaceutical Factory Main Business Overview
13.10.5 Suzhou Fourth Pharmaceutical Factory Latest Developments
13.11 Sandoz
13.11.1 Sandoz Company Information
13.11.2 Sandoz SNRIs Antidepressants Product Portfolios and Specifications
13.11.3 Sandoz SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Sandoz Main Business Overview
13.11.5 Sandoz Latest Developments
13.12 Shandong Xinqi Pharmaceutical
13.12.1 Shandong Xinqi Pharmaceutical Company Information
13.12.2 Shandong Xinqi Pharmaceutical SNRIs Antidepressants Product Portfolios and Specifications
13.12.3 Shandong Xinqi Pharmaceutical SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Shandong Xinqi Pharmaceutical Main Business Overview
13.12.5 Shandong Xinqi Pharmaceutical Latest Developments
13.13 Chongqing Yaoyou Pharmaceutical
13.13.1 Chongqing Yaoyou Pharmaceutical Company Information
13.13.2 Chongqing Yaoyou Pharmaceutical SNRIs Antidepressants Product Portfolios and Specifications
13.13.3 Chongqing Yaoyou Pharmaceutical SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Chongqing Yaoyou Pharmaceutical Main Business Overview
13.13.5 Chongqing Yaoyou Pharmaceutical Latest Developments
13.14 Lupin
13.14.1 Lupin Company Information
13.14.2 Lupin SNRIs Antidepressants Product Portfolios and Specifications
13.14.3 Lupin SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Lupin Main Business Overview
13.14.5 Lupin Latest Developments
13.15 Sun Pharma
13.15.1 Sun Pharma Company Information
13.15.2 Sun Pharma SNRIs Antidepressants Product Portfolios and Specifications
13.15.3 Sun Pharma SNRIs Antidepressants Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Sun Pharma Main Business Overview
13.15.5 Sun Pharma Latest Developments
14 Research Findings and Conclusion
*If Applicable.